

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bulaj et al.

Serial No.: To be assigned

Filed: February 27, 2004

For: CONUS PROTEIN DISULFIDE
ISOMERASE

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2699-5613.1US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV326919655US

Date of Deposit with USPS: February 27, 2004

Person making Deposit: Christopher Haughton

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 6,346,244	Hjort	02-12-2002

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 93/25676	12-23-1993	Merck & Co., Inc.
WO 94/08012	04-14-1994	Research Corp. Technologies, Inc.
WO 95/01420	01-12-1995	Novo Nordisk A/S
WO 95/01425	01-12-1995	Novo Nordisk A/S
WO 97/14431	04-24-1997	Collagen Corp.
WO 97/43426	11-20-1997	Incyte Pharmaceuticals, Inc.
WO 99/46281	09-16-1999	Genentech
WO 01/14564 A2	03-01-2001	Curagen Corp.
WO 02/20731 A2	03-14-2002	Bayer Aktiengesellschaft
EP 0 510 658 B1	10-28-1992	Glockshuber et al.

Other Documents

KARPLUS et al., Assignment of homology to genome sequences using a library of hidden Markov models that represent all proteins of known structure, J. Mol. Biol., November 2, 2001, pp. 903-19, Vol. 313, No. 4, Abstract.

IBA et al., Comparison of strategies for the construction of libraries of artificial antibodies, Immunol. Cell Biol., Apr. 1997, pp. 217-21, Vol. 75, No. 2, Abstract.

JAYAWICKREME et al., Creation and functional screening of a multi-use peptide library, Proc. Natl. Acad. Sci., March 1994, pp. 1614-18, Vol. 91, USA.

KLUG, A, Zinc finger peptides for the regulation of gene expression, J. Mol. Biol., October 22, 1999, pp. 215-18, Vol. 293, No. 2.

OGIWARA et al., Construction and analysis of a profile library characterizing groups of structurally known proteins, *Protein Sci.*, October 1996, pp. 1991-99, Vol. 5, No. 10.

SAUNDER et al., Large-Scale Comparison of Protein Sequence Alignment Algorithms With Structure Alignments, *Proteins: Structure, Function, and Genetics*, 2000, pp. 6-22, Vol. 40.

SCHAFFER et al., Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements, *Nucleic Acids Research*, 2001, pp. 2994-3005, Vol. 29, No. 14, USA.

SMITH et al., Small Binding Proteins Selected form a Combinatorial Repertoire of Knottins Displayed on Phage, *J. Mol. Biol.*, 1998, pp. 317-332, Vol. 277.

VALUEV, et al., ASPD (Artificially Selected Proteins/Peptides Database): a database of proteins and peptides evolved in vitro, *Nucleic Acids Research*, 2002, pp. 200-02, Vol. 30, No. 1.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.:	2699-5612US
Serial No.:	10/456,375
Filing Date:	6/5/2003
Title:	A LIBRARY OF PHYLOGENETICALLY RELATED SEQUENCES

Attorney Docket No.: 2699-5613.1US

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



G. Scott Dorland, Ph.D.

Registration No. 51,622

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: February 27, 2004

GSD/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	To be assigned
Filing Date	February 27, 2004
First Named Inventor	Bulaj et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2699-5613.1US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-6,346,244	Hjort	02-12-2002	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-February 27, 2004-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 93/25676	12-23-1993	Merck & Co., Inc.		
		WO 94/08012	04-14-1994	Research Corp. Technologies, Inc.		
		WO 95/01420	01-12-1995	Novo Nordisk A/S		
		WO 95/01425	01-12-1995	Novo Nordisk A/S		
		WO 97/14431	04-24-1997	Collagen Corp.		
		WO 97/43426	11-20-1997	Incyte Pharmaceuticals, Inc.		
		WO 99/46281	09-16-1999	Genentech		
		WO 01/14564 A2	03-01-2001	Curagen Corp.		
		WO 02/20731 A2	03-14-2002	Bayer Aktiengesellschaft		
		EP 0 510 658 B1	10-28-1992	Glockshuber et al.		

Examiner
SignatureDate
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	To be assigned
Filing Date	February 27, 2004
First Named Inventor	Bulaj et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2699-5613 IIIS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KARPLUS et al., Assignment of homology to genome sequences using a library of hidden Markov models that represent all proteins of known structure, J. Mol. Biol., November 2, 2001, pp. 903-19, Vol. 313, No. 4, Abstract.	
		IBA et al., Comparison of strategies for the construction of libraries of artificial antibodies, Immunol. Cell Biol., Apr. 1997, pp. 217-21, Vol. 75, No. 2, Abstract.	
		JAYAWICKREME et al., Creation and functional screening of a multi-use peptide library, Proc. Natl. Acad. Sci., March 1994, pp. 1614-18, Vol. 91, USA.	
		KLUG, A, Zinc finger peptides for the regulation of gene expression, J. Mol. Biol., October 22, 1999, pp. 215-18, Vol. 293, No. 2.	
		OGIWARA et al., Construction and analysis of a profile library characterizing groups of structurally known proteins, Protein Sci., October 1996, pp. 1991-99, Vol. 5, No. 10.	
		SAUNDER et al., Large-Scale Comparison of Protein Sequence Alignment Algorithms With Structure Alignments, Proteins: Structure, Function, and Genetics, 2000, pp. 6-22, Vol. 40.	
		SCHAFER et al., Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements, Nucleic Acids Research, 2001, pp. 2994-3005, Vol. 29, No. 14, USA.	
		SMITH et al., Small Binding Proteins Selected from a Combinatorial Repertoire of Knottins Displayed on Phage, J. Mol. Biol., 1998, pp. 317-332, Vol. 277.	
		VALUEV, et al., ASPD (Artificially Selected Proteins/Peptides Database): a database of proteins and peptides evolved in vitro, Nucleic Acids Research, 2002, pp. 200-02, Vol. 30, No. 1.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.